Repro Med Systems Stock Earnings Reports

KORU reported a strong Q1 2026 with $11.8M revenue, up 22% year-over-year, driven by domestic SCIg share gains, a 35% increase in international core (prefilled syringe conversions in Europe), and a 166% increase in PST clinical trial revenues. The company ended the quarter with $8.8M cash and used only $0.1M in cash, and adjusted EBITDA was essentially breakeven (−$10k). Management reiterated full-year 2026 guidance: revenue $47.5M–$50M (15%–22% growth), gross margin 61%–63%, and positive adjusted EBITDA and positive cash flow. Strategic priorities remain a three-pillar plan: protect and grow the U.S. core, expand internationally (EU conversions and new markets), and add non-Ig drugs to the Freedom Infusion System. The non-Ig pipeline now includes eight active opportunities representing an estimated >6 million annual infusions (potentially ~2x current SCIg revenue if realized). Key regulatory and development updates: 510(k) submitted for deferoxamine; Phesgo 510(k) under active FDA review; two pharma collaborators advanced assets to Phase III; vancomycin removed from development pipeline. Leadership transition: CEO Linda Tharby confirmed this was her final call and Adam Kalbermatten will become CEO on July 1, with management expressing confidence in the transition and the company’s long-term targets (including a $100M revenue goal and margin/EBITDA targets). Risks noted include variability in international uptake, PST revenue timing, and geopolitical/freight impacts (Middle East caution).